

The 11th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA (COMy)

Young Patient with Multiple Myeloma Without Transplant Access: **Clinical Evolution with Persistent Positive MRD (MRD+)**

Maribel Molina, Martha Cueva, Claudia Morales, Claudia Otoya

National Hospital Arzobispo Loayza, Lima, Peru

BACKGROUND AND PURPOSE

Background: Multiple myeloma (MM) in young adults is rare and typically presents with heterogeneous clinical outcomes. Persistent MRD+ despite complete clinical response requires close monitoring.

Puporse: To present the case of a young MM patient with renal failure who achieved and maintained a complete hematological and renal response (RCH-RCR) with persistent MRD+, without access to transplant.


DESCRIPTION

A 25-year-old male with 4 months of nausea and vomiting, weight loss, intermittent hematuria, recently diagnosed with hypertension. Labs showed anemia (Hb 9.2 g/dL) and altered renal function (Cr 2.5 mg/dl, Proteinuria 5043 mg/24h), albumin 4.5 mg/dl and β2-microglobulin 5.6 mg/L. Renal biopsy revealed Lambda light chain monoclonal lg deposition glomerulopathy and congo red negative staining. Immunofixation test confirmed monoclonal Lambda gammopathy. Light Chain: Kappa 38.9mg/L and Lambda 425.6mg/L. Bone marrow aspirate: 11% plasma cells (Lambda-restricted confirmed by flow cytometry). No bone lesions or hypercalcemia.

The patient received 12 cycles of VTD (Bortezomib, thalidomide, Dexamethasone), achieving RCH-RCR with MRD+, in the fourth and seventh cycle respectively. Due to progressive increase proteinuria (up to 939 mg/24h) and bone marrow aspirate with 15% plasma cells, he received 4 cycles of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) with RCH-RCR, MRD+.

Currently, he remains in RCH-RCR, MRD+, with maintenance therapy Thalidomide for 3 months, asymptomatic with stable proteinuria and normal free light chain ratio.





CONCLUSION

Standard regimens can lead to complete responses in young MM patients without access to transplant. Despite MRD+, disease control and improved quality of life are possible. Proteinuria may serve as a biomarker for relapse in MM.



1. Engelhardt M, Kortüm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024 Aug 1;109(8):2420-2435.

2. Fazio F, Gherardini M, Rossi E, Za T, Di Landro F, Morè S, Manieri VM, Liberatore C, Chavez MG, Bongarzoni V, et al. Long-Term Survival with Multiple Myeloma: An Italian Experience. Cancers. 2025; 17(3):354.

CONTACT

Email: hematologa.mmolina@gmail.com

Figure 1. Evolution of hemoglobin,

creatinine, and proteinuria levels

https://comylive.cme-congresses.com